Skip to content

Total at other companies

Edwards Lifesciences logo
Edwards LifesciencesEW

Other financials

Income statement

See full
Revenue$199.4M+25.7%
Gross profit$141.4M+29.4%
Operating income-$16.2M+50.3%
Net income-$13.9M+54.6%
EPS (diluted)-$0.43+55.7%

Balance sheet

See full
Cash & equivalents$248.5M-35.2%
Total debt$79.0M-10.5%
Total equity$161.2M+86.0%
Total assets$1.0B+8.7%

Cash flow

See full
Operating cash flow-$26.2M-232%
CapEx$6.9M-26.7%
Free cash flow-$33.1M-91.1%

Valuation

See full
Market cap$3.62B+16.0%

Profitability

See full
Gross margin71%+1.6pp
Operating margin-5.5%-2.2pp
Net margin-7.3%-3.1pp
FCF margin2.4%

Returns & leverage

See full
Return on equity-53.1%-17.4pp
Debt / equity0.5×-0.5×
Current ratio5.2×-0.5×

Where this comes from

Reported directly by iRhythm Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: iRhythm Holdings, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about iRhythm Holdings, Inc. 's total.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is iRhythm Holdings, Inc. 's total?
iRhythm Holdings, Inc. (IRTC) reported total of $455.35M in Q1 2026.
How has iRhythm Holdings, Inc. 's total changed year-over-year?
iRhythm Holdings, Inc. 's total increased by 42.2% year-over-year, from $320.21M to $455.35M.
What is the long-term trend for iRhythm Holdings, Inc. 's total?
Over 5 years (2020 to 2025), iRhythm Holdings, Inc. 's total has grown at a 9.8% compound annual growth rate (CAGR), from $306.4M to $489.89M.